8-K: Turnstone Biologics Prioritizes Lead Program, Extends Cash Runway into 2026 After Restructuring

Turnstone Biologics announced a corporate restructuring to focus on its TIDAL-01 program, extending its cash runway into the second quarter of 2026.

Summary

• Turnstone Biologics reported its third quarter 2024 financial results and provided a business update.
• The company has decided to prioritize its TIDAL-01 program and has undergone a corporate restructuring.
• This restructuring included a 60% workforce reduction to extend the company's cash runway.
• Turnstone's cash, cash equivalents, and short-term investments totaled $45.3 million as of September 30, 2024.
• The company expects its cash to fund operations into the second quarter of 2026.
• Initial data from the STARLING trial showed a 25% overall response rate and a 50% disease control rate in heavily pre-treated colorectal cancer patients.
• One patient in the STARLING trial achieved a complete response and has remained progression-free for over a year.
• Research and development expenses for the quarter were $14.4 million, slightly up from $14.2 million in the same period last year.
• General and administrative expenses decreased to $3.9 million from $4.8 million in the same quarter of the previous year.
• The net loss for the quarter was $17.0 million, compared to a net loss of $17.3 million in the same period of 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the promising clinical data and extended cash runway, but tempered by the significant workforce reduction and ongoing losses.

Positives

• The company has extended its cash runway into the second quarter of 2026, providing financial stability.
• The initial data from the STARLING trial showed promising results, including a complete response in one patient.
• The company is focusing on its lead program, TIDAL-01, which could lead to significant value creation.
• The company has made key leadership changes to support the new strategy.
• The company presented at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting, showcasing their ongoing clinical efforts.

Negatives

• The company implemented a 60% workforce reduction, which may impact morale and productivity.
• The company reported a net loss of $17.0 million for the quarter.
• The company's cash position has decreased significantly from $94.8 million at the end of 2023 to $45.3 million as of September 30, 2024.

Risks

• The company's ability to achieve projected cost savings from the workforce reduction is uncertain.
• Clinical trial results may differ from preclinical or early clinical results.
• There is no guarantee that the company's product candidates will receive regulatory approvals.
• The company may need additional capital to achieve its goals.
• Macroeconomic conditions and global health concerns could impact the company's operations.

Future Outlook

The company expects its cash runway to support operations and clinical development through the second quarter of 2026 and anticipates sharing its next clinical update in the first half of 2025.

Management Comments

• Sammy Farah, M.B.A., Ph.D., stated that the corporate restructuring and focus on the Phase 1 program, TIDAL-01, puts the company on the path to significant value creation.
• Sammy Farah also noted that the extended cash runway enables the company to achieve potential key clinical milestones.
• Management believes the initial clinical data strengthens the competitive profile of their next-generation selected TIL technology.

Industry Context

The announcement comes amid a growing interest in TIL therapy for solid tumors, with Turnstone positioning itself as a leader in the next-generation of this approach. The company's focus on selected TILs aims to improve upon the limitations of first-generation bulk TIL therapies.

Comparison to Industry Standards

• The standard of care for the patient population in the STARLING trial has an overall response rate of 1-6% and a median progression-free survival of 2-5.6 months.
• Turnstone's STARLING trial showed a 25% overall response rate and a 50% disease control rate, which is significantly better than the current standard of care.
• The complete response and progression-free survival of over one year in one patient is also notable compared to the standard of care.

Management Changes

Stakeholder Impact

• Shareholders may view the restructuring and focus on TIDAL-01 positively, but the workforce reduction may raise concerns.
• Employees have been significantly impacted by the 60% workforce reduction.
• Patients may benefit from the development of the TIDAL-01 program.
• Suppliers and creditors may be impacted by the company's restructuring.

Next Steps

• The company plans to continue the development of the TIDAL-01 program.
• Turnstone expects to share its next clinical update in the first half of 2025.

Key Dates

Keywords

Turnstone Biologics, TIDAL-01, Selected TIL, cancer therapy, clinical trials, corporate restructuring, cash runway, colorectal cancer, immunotherapy, biotechnology